TGNA:FRA
Transgene SA
0,70 €
arrow_downward
-0,99%(-0,0070) 1D
30. 9., 8:02:11 GMT+2 · EUR
search
Všechny symboly
1D
5D
1M
6M
YTD
1R
5R
MAX
| Symbol | Cena | Změna | Změna (%) |
|---|
insights_autoGenerování hlavních statistik pro TGNA…
Otevřít
0,70 €
Max.
0,70 €
Min.
0,70 €
Trž. kap.
203,35 mil.
Prům. obj.
0,00
Objem
0,00
52týd. max.
1,48 €
52týd. min.
0,60 €
EPS
-0,17 €
Počet zaměstnanců
145
Otevřít
0,70 €
Max.
0,70 €
Min.
0,70 €
Trž. kap.
203,35 mil.
Prům. obj.
0,00
Objem
0,00
52týd. max.
1,48 €
52týd. min.
0,60 €
EPS
-0,17 €
Počet zaměstnanců
145
Profil
Transgene S.A. is a French biotechnology company founded in 1979. It is based in Illkirch-Graffenstaden, near Strasbourg, Alsace. The company develops and manufactures immunotherapies for the treatment of cancer. Based on viral vectors, these therapies stimulate the immune defenses of patients to specifically target cancer cells.
Transgene has two technological platforms based on these respective approaches: individual therapeutic vaccines, shared antigens cancer vaccines oncolytic viruses.
Transgene's portfolio consists of four products currently in clinical development. Its lead product TG4050, a neoantigen individualized therapeutic cancer vaccine is currently being developed in a randomized Phase I/II trial in the adjuvant treatment of head and neck cancer.
The company is listed on the regulated market of Euronext in Paris. Wikipedia
Informace o Transgene SA